Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | July 31, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date July 31, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,252 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745 Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0 F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 1,507 |
Reported balance
After 2024-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,852 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,019 Underlying: Common Stock · 6,852 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,460 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,506 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,616 Underlying: Common Stock · 1,506 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,055 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 215 | $24.50 | $5,267.01 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.30 to $24.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,067 | $23.71 | $238,686.56 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.28 to $24.002, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,870 | $2.14 | $16,841.80 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-004513 · form4-03082023_060307.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Options (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $25.57 | $0.00 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2033-02-06 F8 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,871 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,478 Underlying: Common Stock · 1,019 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,122 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,961 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,426 | $25.02 | $35,678.66 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.96 to $25.155, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,858 | $24.52 | $217,202.59 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.95 to $24.92, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,872 | $2.14 | $16,846.08 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-23-002170 · form4-02082023_060209.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,570 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,724 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,497 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,629 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,866 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,792 | $26.95 | $75,253.89 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.48 to $27.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 7,492 | $25.62 | $191,948.79 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,792 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.36 to $26.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,871 | $2.14 | $16,843.94 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,413 | $1.74 | $4,198.62 |
DisclosureSEC source: 0001415889-23-000709 · form4-01092023_060111.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,059 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012550 · form4-12142022_061201.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,577 Underlying: Common Stock · 2,059 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 907 | $30.26 | $27,443.37 |
DisclosureSEC source: 0001415889-22-012550 · form4-12142022_061201.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.62 to $30.61, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,132 | $28.83 | $32,631.71 |
DisclosureSEC source: 0001415889-22-012550 · form4-12142022_061201.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.30 to $29.265, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 20 | $25.82 | $516.40 |
DisclosureSEC source: 0001415889-22-012550 · form4-12142022_061201.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,039 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,059 | $2.14 | $4,406.26 |
DisclosureSEC source: 0001415889-22-012550 · form4-12142022_061201.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 394 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,636 Underlying: Common Stock · 394 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 394 | $25.03 | $9,860.84 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 394 | $2.14 | $843.16 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,030 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,178 | $24.08 | $76,532.91 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,199 | $22.56 | $72,178.40 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,178 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.845, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,695 | $21.63 | $58,302.28 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,377 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 928 | $20.94 | $19,435.20 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,072 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.235 to $21.22, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-22-012429 · form4-12122022_061202.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,570 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,030 Underlying: Common Stock · 36,570 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F9 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,515 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,136 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 615 | $18.29 | $11,249.64 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.192 to $18.33, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 36,115 | $17.80 | $642,861.45 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.191 to $18.16, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,259 | $16.90 | $21,275.09 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,730 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.19 to $17.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,011 | $15.61 | $31,386.28 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,989 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.152 to $15.98, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 37,588 | $2.14 | $80,438.32 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,412 | $1.74 | $4,196.88 |
DisclosureSEC source: 0001415889-22-012273 · form4-12082022_061206.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,198 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · derivative · entry 11 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,600 Underlying: Common Stock · 6,198 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.